We also discuss the underlying mechanisms of the aberrant expression of miRs that can negatively impact AMPK, as well as the therapeutic potential of targeting the miR-AMPK pathway for NAFLD/NASH. This evidence concerns the gene PRKAB1 and metabolic dysfunction-associated steatotic liver disease.